OR WAIT 15 SECS
The SCIEX PA 800 Plus Pharmaceutical Analysis system is used to identify and quantify glycans to ensure therapeutic efficacy.
SCIEX announced the launch of the SCIEX PA 800 Plus Pharmaceutical Analysis System on Jan. 24, 2017. The system can accelerate workflow through glycan release and labeling, followed by separation and quantitation, and glycan identification. SCIEX’s solution enables researchers in analytical method development and quality control labs to identify and quantify glycans associated with biologics to ensure therapeutic efficacy.
The analysis system averages one hour for sample preparation of up to 96 separations. Automated glycan identification eliminates the need for manual, glycan database searches, and eliminates the potential for human error. Proper glycosylation is critical for the efficacy, immunogenicity, and clearance of biologics. Incorrect glycan species associated with biologics, such as a monoclonal antibody (mAb), can lead to an increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity. Using a custom internal standard, glucose unit (GU) calculations can be performed on aligned data directly in the SCIEX PA 800 Plus software.